Investment trust RTW Biotech Opportunities (LON:RTW) scored yet another win as Biomarin Pharmaceutical (NASDAQ:BMRN) snapped up private portfolio company Alesta Therapeutics for $490 million. Alesta is developing novel oral small-molecule therapies for underserved rare diseases. This transaction represents the sixth portfolio acquisition from RTW Bio’s portfolio in 2026. Sixth M&A transaction of 2026 Biomarin Pharmaceutical … Continue reading RTW Biotech Opportunities scores again as Biomarin buys Alesta